Redx Pharma Nominates First Development Compound To Treat Fibrosis

LONDON (Alliance News) - Redx Pharma PLC said Wednesday that it nominated the first development ...

Alliance News 14 November, 2018 | 11:17AM
Email Form

LONDON (Alliance News) - Redx Pharma PLC said Wednesday that it nominated the first development compound to treat fibrosis.

The new candidate, RXC006, is an oral porcupine inhibitor that will be developed as a first-in-class treatment for idiopathic pulmonary fibrosis, a severe and life-threatening chronic lung condition with very poor prognosis and limited treatment options, the drug development company explained.

The company will present pre-clinical data, which showed that the compound is "very potent and highly effective", at the Anti-Fibrotic Drug Development summit, in the US, at the end of November.

Furthermore, the first in-man study for the product have been earmarked for 2020.

Redx shares were trading down 2.1% at 6.95 pence each.

By Elena Cherubini; elenacherubini@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Redx Pharma PLC 58.00 GBX 0.87 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies